Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Astellas Pharma financials data including stock price, CreditSafe score, income statement, balance sheet, cash flow, and acquistions and subsidiaries.

Stock Price

¥1.5 K


Market Capitalization

¥2.7 T



¥1.6 T

FY, 2024

CreditSafe Score

Score changed on Jul 17, 2024
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn more

Financial Statements

USDFY, 2017FY, 2018FY, 2019FY, 2020FY, 2022FY, 2023FY, 2024
Cost of goods sold(229.4B)(228.6B)(210.3B)(173.4B)173.3B182.6B134.6B
Gross profit1.1T1.1T1.1T1.1T1.2T1.3T1.5T
Gross profit margin, %82.4%82.5%84.5%86.7%89.0%88.2%92.8%
Operating expense total(699.1B)(698.9B)(745.5B)(747.2B)824.3B969.8B1.2T
Depreciation and amortization(143.1B)(110.1B)(101.4B)(198.2B)182.8B228.1B256.7B
EBITDA margin, %28.4%28.9%27.0%26.9%25.5%24.4%17.6%
EBIT margin, %16.2%17.5%19.4%11.1%11.4%9.4%1.6%
Interest income1.6B2.7B2.2B683.0M997.0M7.9B11.5B
Interest expense(2.2B)(2.1B)4.9B3.6B12.0B
Pre tax profit218.1B249.0B245.4B145.3B156.9B132.4B25.0B
Income tax expense(53.4B)(26.7B)(49.9B)(24.7B)32.8B33.6B7.9B
Net Income164.7B222.3B195.4B120.6B124.1B98.7B17.0B

Acquisitions & Subsidiaries

Company nameDateDeal size
LoremDec 23, 2021$40.0M
IpsumJan 18, 2022$30.0M
Lorem IpsumFeb 18, 2022$25.0M
DolorOct 21, 2021$60.0M
Premium Content only available in Craft’s Intelligence Portal
View acquisitions and subsidiaries by company, date, and deal size.
Understanding this data enables better supplier & customer negotiations and helps identify potential opportunities or market risks for your firm.
Learn more

Footer menu